AdhexPharma is an independent pharmaceutical company specialized in Transdermal Delivery Systems (TDS), topical patches and Oral Thin Films (OTF).

Our role is to allow Pharma and Biotech companies innovating thanks to our 3 Drug Delivery Technologies:

  • Transdermal patches with systemic activity for sustained delivery
  • Topical patches with local activity for controlled delivery and accurate dosing
  • Oral Thin Films with systemic activity for rapid delivery

Latest news


AdhexPharma and AMW announce strategic partnership for transdermal delivery systems

Find all informations here : https://www.adhexpharma.com/wp-content/uploads/2021/11/APH_AMW.pdf


February 2021

AdhexPharma in ‘Les Echos’

For the 4th year in a row, AdhexPharma is among the top 500 fastest growing companies in France, ranking 211th in the "Champions of Growth" list issued by the newspaper 'Les Echos', to which we would like to express our sincere gratitude. This also makes us 2nd in the Chemical and Pharmaceutical sector. We would also like to thank our partners once again for their trust. https://www.lesechos.fr/weekend/business-story/les-champions-de-la-croissance-2021-dans-la-chimie-et-la-pharmacie-1287639#utm_source=le%3Alec0f&utm_medium=click&utm_campaign=share-links_linkedin


September 2020

ISO 13485

We are proud to have been awarded ISO 13485 certification, an internationally recognised standard that ensures services meet the needs of clients through an effective quality management system for medical devices.


Our profile

  • AdhexPharma is a drug delivery company specialized in Transdermal Delivery Systems (TDS), topical patches and Oral Thin Films (OTF). We currently have 4 approved drug products, several development programs and more than 27 years of experience in this field.
  • We are a privately-owned company, part of Burgundy Ventures, a Holding company created in 2002 for the purpose of acquiring Adhex Technologies to the Fournier Group.
  • Adhex Technologies, our sister company, is a 80M€ turnover company with more than 500 employees around the world, active in coating & converting adhesive products for 3 markets (healthcare, automotive and industry).

AdhexPharma operations are located in France at the following sites:

  • R&D and Manufacturing site is located in Bourgogne, in the Dijon area

    42—44, rue de Longvic
    21 300 Chenôve
  • Head Office
    (Burgundy Ventures Holding Group)

    30, rue de Lübeck
    75 016 Paris

Our history

  • Decade 1980
  • Fournier Pharma set up an R&D team dedicated to the development of transdermal systems for various therapeutic applications


  • Decade 1990
  • Building of a dedicated facility to manufacture transdermal systems at the industrial scale
    Approval & launch of estradiol patch in Europe in 1994
    FDA approval & US launch of estradiol patch (1998)


  • 2005
  • Acquisition of Fournier Pharma by Solvay Pharmaceuticals


  • 2008
  • Acquisition of the transdermal activity of Solvay Pharmaceuticals by Burgundy Ventures and creation of PlastoPharma


  • 2012—2014
  • Approval and launch in Europe of Lidocaine/Prilocaine patch for local anesthesia
    Start of 1st development project with a US pharma company


  • 2015
  • Approval of 4th drug product in EU
    Creation of Pilot Scale Factory for TDS & OTF projects


  • 2016—2017
  • Filing of US drug product dossier
    FDA Pre Approval Inspection PAI with no 483 form
    New building doubling the size of clean rooms
    Company name change: PlastoPharma becomes AdhexPharma in June 2017

Regulatory and Quality

  • AdhexPharma is operating under cGMP condition with an authorized pharmaceutical production facility subject to routine GMP inspections as defined by the European/French Health Authorities and FDA.

    French Health authorities (ANSM) :

    Approval since 1994
    Audited every 2 years

    FDA :

    Approval and supply of the US market between 1998 and 2006
    PAI in January 2017 without 483 form
  • Our GMP certificate allows us to develop and manufacture both Human Investigational Medicinal products (clinical batches) and commercial products for the following 3 dosage forms:

    Transdermal patches
    Impregnated matrices
    Orodispersible films

  • We are authorized to handle high-potent and toxic drug substances, such as hormones and nicotine

    Depending on its partners’ needs, AdhexPharma can provide its regulatory expertise from early development stage (formulation and pre-clinical evaluation) with the design of regulatory strategies specific to these dosage forms, until the product registration phase with the provision and assembly of complete registration dossiers.

Key Figures


years of experience
in the drug delivery field


who trusted us since 2008


approved products
since 2008

Drug delivery technologies



with systemic activity for sustained delivery

Transdermal patches are developed to deliver drugs systemically and can present for certain disease conditions major advantages over other drug delivery. For several molecules, the transdermal route offers key advantages over oral administration.



With local activity for controlled delivery and accurate dosing

Topical patches are developed to deliver drugs to a local site of action and can present for certain disease conditions major advantages over other drug delivery such as oral or traditional topical forms like gels or creams.



With systemic activity for rapid delivery

An Oral Thin Film (OTF) is a very thin film, composed of a mono or multi-layer polymeric matrix, which is applied in the mouth. OTF are often water based soluble polymers designed to rapidly deliver drugs systematically.

Drug delivery services



Full-service partner from pre-formulation to commercial supply

Are you looking for a drug delivery partner to evaluate your drug candidate for the transdermal or oral route? Are you searching to improve the delivery route of your existing drug product?



Increasing development speed with robust and flexible pilot equipment

How to handle quick and efficient project management and GMP requirements for exploratory Phase 1 clinical studies and close the gap between R&D formula and full-scale industrial production?



A reliable partner for large scale manufacture during commercial stage

Located in France on the same 9 hectares campus as our sister company Adhex Technologies, AdhexPharma pharmaceutical site is dedicated to the manufacture of patches, impregnated matrices and oral films under cGMP conditions.



  • One of our key goals of partnering is to utilize our internal product development expertise and manufacturing capabilities to help you leverage your company’s scientific advancements into new, safe and effective products.
  • Our investment supports alliances with the academic community as well as the biotechnology, pharmaceutical, and the broader life sciences industries.
  • AdhexPharma moves quickly to evaluate if your compound is a good candidate for transdermal, topical or oral thin films delivery. We aim to be your partner of choice and would welcome the opportunity to meet you to discuss potential collaboration.

Please contact us
(Business Development Manager – AdhexPharma)


March 22–25, 2021

BIO Spring Europe
Contact us


If you have talent and imagination and are ready to respond to the challenges of a promising career, send us your CV and cover letter at the address below:


Index de l’égalité Femmes/Hommes


 Depuis le 1er mars 2020, AdhexPharma publie son Index de l’égalité femmes/hommes qui est le résultat des 4 indicateurs rendus obligatoires dans le cadre de la loi « Pour la liberté de choisir son avenir professionnel ».

There is a wide range of professional opportunities in our company.


(R&D and Manufacturing)

42 − 44, rue de Longvic
21 300 Chenôve, France

Head Office
(Burgundy Ventures Holding Group)

30, rue de Lübeck
75 016 Paris, France

Copyright 2016 © AdhexPharma.
All rights reserved.

Webdesign : Atelier Tout va bien
Web development : Pierre GD